Quarterly report pursuant to Section 13 or 15(d)

Warrants (Details Narrative)

v3.10.0.1
Warrants (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Jan. 26, 2018
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Class of Warrant or Right [Line Items]          
Warrant exercised for shares   5,000   5,000  
Proceeds from warrant exercise   $ 5,000   $ 5,000  
Warrants exercised    
Warrant to purchase of common stock   2,283,500   2,283,500  
Weighted average exercise price of warrants   $ 6.34   $ 6.34  
Weighted average remaining life of warrants       3 years 1 month 20 days  
Additional paid in capital, fair value of warrant issued       $ 6,215,225  
Cystic Fibrosis Foundation Warrants [Member]          
Class of Warrant or Right [Line Items]          
Warrant to purchase of common stock 1,000,000 1,000,000   1,000,000  
Weighted average exercise price of warrants $ 13.20 $ 13.20   $ 13.20  
Warrant exercisable shares of common stock 500,000 500,000   500,000  
Warrant expires date Jan. 26, 2025        
Additional paid in capital, fair value of warrant issued       $ 6,215,225  
Cystic Fibrosis Foundation Warrants [Member] | Investment Agreement [Member]          
Class of Warrant or Right [Line Items]          
Warrant exercisable shares of common stock 500,000 500,000   500,000  
Warrant expires date       Jan. 26, 2025